Teprotumumab for Thyroid-Associated Ophthalmopathy
Teprotumumab for Thyroid-Associated Ophthalmopathy
About this item
Full title
Author / Creator
Smith, Terry J , Kahaly, George J , Ezra, Daniel G , Fleming, James C , Dailey, Roger A , Tang, Rosa A , Harris, Gerald J , Antonelli, Alessandro , Salvi, Mario , Goldberg, Robert A , Gigantelli, James W , Couch, Steven M , Shriver, Erin M , Hayek, Brent R , Hink, Eric M , Woodward, Richard M , Gabriel, Kathleen , Magni, Guido and Douglas, Raymond S
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In patients with thyroid-associated ophthalmopathy, responses to treatment are rare and usually minor. Teprotumumab, an antibody to the insulin-like growth factor I receptor, led to significant responses in 69% of patients and to decreased proptosis.
Medical therapies for moderate-to-severe thyroid-associated ophthalmopathy (Graves’ orbitopathy)...
Alternative Titles
Full title
Teprotumumab for Thyroid-Associated Ophthalmopathy
Authors, Artists and Contributors
Author / Creator
Kahaly, George J
Ezra, Daniel G
Fleming, James C
Dailey, Roger A
Tang, Rosa A
Harris, Gerald J
Antonelli, Alessandro
Salvi, Mario
Goldberg, Robert A
Gigantelli, James W
Couch, Steven M
Shriver, Erin M
Hayek, Brent R
Hink, Eric M
Woodward, Richard M
Gabriel, Kathleen
Magni, Guido
Douglas, Raymond S
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5718164
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5718164
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1614949
